Search

Your search keyword '"Schellenberg D"' showing total 515 results

Search Constraints

Start Over You searched for: Author "Schellenberg D" Remove constraint Author: "Schellenberg D"
515 results on '"Schellenberg D"'

Search Results

1. The silent burden of anaemia in Tanzanian children: a community-based study

2. Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial

3. Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial

7. Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial

11. Stereotactic Ablative Radiotherapy for Oligo-Progressive Cancers: Results of the Randomized Phase II STOP Trial

13. OC-0268 Should OARs be prioritized in SABR for oligometastases? A secondary analysis of the SABR-5 trial

14. Predictors of Early Polymetastatic Relapse Following Stereotactic Ablative Radiotherapy for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial

15. Development of a Support Vector Machine-Based Tool for Survival Prediction after Stereotactic Body Radiotherapy for Liver Metastases Using Multi-Institutional Data

16. Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR): Overall Survival Results of the SABR-5 Trial

19. Development of Nomograms to Predict Polymetastatic Progression Free Survival and Overall Survival in Patients Treated with Stereotactic Ablative Radiotherapy for Oligometastatic or Oligoprogressive Cancer

20. OC-0104 Stereotactic radiation for treatment of oligometastases (SABR-COMET) – Extended long-term outcomes

21. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

22. Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for up to 5 Oligometastases: Preliminary Results of the SABR-5 Trial

23. Cost-Effectiveness of SABR in Oligometastatic Cancer: An Economic Analysis Based on Long-Term Results of the SABR-COMET Trial

28. Building momentum for malaria vaccine research and development: key considerations

35. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Randomized Trial

37. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

38. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

39. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

47. Quality of Life Outcomes after Stereotactic Ablative Radiotherapy (SABR) vs. Standard of Care Palliative Treatments: A Secondary Analysis of the SABR-COMET Randomized Trial

50. Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of SABR-Comet

Catalog

Books, media, physical & digital resources